Affordable Access

[Clinical evaluation of a new carbapenem, meropenem, in infants and children].

Authors
Type
Published Article
Journal
The Japanese journal of antibiotics
Publication Date
Volume
45
Issue
7
Pages
866–879
Identifiers
PMID: 1522678
Source
Medline
License
Unknown

Abstract

A new carbapenem antibiotic, meropenem (MEPM), was evaluated for its safety and efficacy in 33 infants and children. MEPM was effective in all the 32 evaluable cases including 4 cases of bacterial meningitis and 5 cases of Pseudomonas aeruginosa infections. The mean half life of plasma concentrations of MEPM was 0.84 +/- 0.09 hours after 30 minutes intravenous drip infusion. Mild diarrhea (2 cases), transient elevation of transaminases (8 cases), and transient eosinophilia (2 cases) were associated with the MEPM therapy, but none of them was problematic. These data suggest that MEPM is safe in infants and children and could be one of the therapeutic agents for severe infections or infections in compromised hosts.

Statistics

Seen <100 times